stockmarketproxy
/
IONSNasdaq SEC EDGAR

IONIS PHARMACEUTICALS INC

Pharmaceutical Preparations·CARLSBAD, CA·FY end 12/31·CIK 874015
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$203.3M$226.6M$324.5M$151.9M$440.0M
Gross Profit——————
Operating Income-$214.5M-$110.8M-$6.1M-$208.0M$220.6M
Net Income-$229.4M-$104.3M-$9.3M-$269.7M$224.6M
Operating CF-$268.6M-$500.9M-$307.5M-$274.4M$30.8M
Capex$51.4M$45.3M$23.8M$15.7M$12.0M
Free Cash Flow-$320.0M-$546.2M-$331.3M-$290.1M$18.8M
Buybacks———$0$0
Dividends——————
Gross Margin——————
Operating Margin-105.5%-48.9%-1.9%-137.0%50.1%
Net Margin-112.8%-46.1%-2.9%-177.6%51.0%
FCF Margin-157.4%-241.1%-102.1%-191.0%4.3%
R&D / Revenue450.3%———145.0%
Effective Tax-0.5%1.3%-9.7%-4.5%1.9%
Debt / Equity6.424.176.594.14—
Buybacks / FCF———0.0%0.0%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
IONS
44:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
IONS
$0M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
IONS
-112.8%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%